Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gain Therapeutics (GANX) Operating Expenses (2020 - 2025)

Gain Therapeutics (GANX) has 6 years of Operating Expenses data on record, last reported at $4.8 million in Q3 2025.

  • For Q3 2025, Operating Expenses rose 7.33% year-over-year to $4.8 million; the TTM value through Sep 2025 reached $17.6 million, down 17.97%, while the annual FY2024 figure was $20.4 million, 8.78% down from the prior year.
  • Operating Expenses reached $4.8 million in Q3 2025 per GANX's latest filing, down from $5.1 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $8.2 million in Q2 2024 and bottomed at $2.5 million in Q1 2021.
  • Average Operating Expenses over 5 years is $4.7 million, with a median of $4.6 million recorded in 2022.
  • Peak YoY movement for Operating Expenses: skyrocketed 568.8% in 2021, then plummeted 37.8% in 2025.
  • A 5-year view of Operating Expenses shows it stood at $3.3 million in 2021, then soared by 40.26% to $4.6 million in 2022, then decreased by 3.38% to $4.4 million in 2023, then decreased by 24.42% to $3.3 million in 2024, then surged by 43.67% to $4.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Expenses were $4.8 million in Q3 2025, $5.1 million in Q2 2025, and $4.4 million in Q1 2025.